Chirfi Guindo
Net Worth
Last updated:
What is Chirfi Guindo net worth?
The estimated net worth of Mr. Chirfi Guindo is at least $8,595,011 as of 18 Feb 2022. He owns shares worth $405,011 as insider and has received compensation worth at least $8,190,000 in Biogen Inc..
What is the salary of Chirfi Guindo?
Mr. Chirfi Guindo salary is $1,170,000 per year as Executive Vice President of Global Product Strategy & Commercialization in Biogen Inc..
How old is Chirfi Guindo?
Mr. Chirfi Guindo is 59 years old, born in 1966.
What stocks does Chirfi Guindo currently own?
As insider, Mr. Chirfi Guindo owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Biogen Inc. (BIIB) | Executive Vice President of Global Product Strategy & Commercialization | 2,919 | $138.75 | $405,011 |
What does Biogen Inc. do?
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB135, BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, Lecanemab, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and BIIB131 to treat acute neurology; BIIB074 for neuropathic pain; and BYOOVIZ, BIIB800, and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Chirfi Guindo insider trading
Biogen Inc.
Mr. Chirfi Guindo has made only one insider trade between 2018-2022, according to the Form 4 filled with the SEC.
As of 18 Feb 2022 he still owns at least 2,919 units of BIIB stock.
Biogen key executives
Biogen Inc. executives and other stock owners filed with the SEC:
- Mr. Chirfi Guindo (59) Executive Vice President of Global Product Strategy & Commercialization
- Mr. Michael R. McDonnell (61) Executive Vice President & Chief Financial Officer
- Mr. Michel Vounatsos (63) Chief Executive Officer & Director
- Ms. Susan H. Alexander (68) Executive Vice President, Chief Legal Officer & Sec.